Xue Zhang

Dr. Xue Zhang


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in European Journal of Pharmacology
Verified
Journal Article
Closed access
TWTingting Wang
Tingting Wang
DQDi Qi
Di Qi
XHXueyuan Hu
Xueyuan Hu
NLNa Li
Na Li
XZXue Zhang
Xue Zhang
JZJingqing Zhang
Jingqing Zhang

1 April 2016
Verified
Journal Article
Closed access
XZXue Zhang
Xue Zhang
HLHong-Ming Liu
Hong-Ming Liu
TLTing-Ting Lei
Ting-Ting Lei
JFJiao Feng
Jiao Feng
JZJing-Qing Zhang
Jing-Qing Zhang

14 August 2020 in medRxiv
Verified
Preprint
Open access
PDF file
JOJing Ouyang
Jing Ouyang
XSXuefeng Shan
Xuefeng Shan
XWXin Wang
Xin Wang
XZXue Zhang
Xue Zhang
YCYaling Chen
Yaling Chen
BZBen Zhang
Ben Zhang
Background: The present study aim to comprehensively report the epidemiological and clinical characteristics of the COVID-19 patients and to develop a multi-feature fusion model for predicting the critical ill probability.Methods: It was a retrospective cohort study that incorporating the laboratory-confirmed COVID-19 patients in the Chongqing Public Health Medical Center. The prediction model was constructed with least absolute shrinkage and selection operator (LASSO) logistic regression method and the model was further tested in the validation cohort. The performance was evaluated by the receiver operating curve (ROC), calibration curve and decision curve analysis (DCA).Results: A total of 217 patients were included in the study. During the treatment, 34 patients were admitted to intensive care unit (ICU) and no developed death. A model incorporating the demographic and clinical characteristics, imaging features and laboratory findings were constructed to predict the critical ill probability and it was proved to have good calibration, discrimination ability and clinic use.Conclusions: The prevalence of critical ill was relatively high and the model may help the clinicians to identify the patients with high risk for developing the critical ill, thus to conduct timely and targeted treatment to reduce the mortality rate.

29 October 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
CXChao Xia
Chao Xia
XFXiaobo Fan
Xiaobo Fan
FCFang Cheng
Fang Cheng
SYSen Yang
Sen Yang
XZXue Zhang
Xue Zhang
YCYemiao CHEN
Yemiao CHEN
Tuberculosis (TB) remains the leading cause of death among people living with HIV (PLWH) despite effective antiretroviral therapy (ART), with HIV infection increasing the risk of active TB by 16 to 27-fold. Even among virologically suppressed individuals on ART, the risk remains 4 to 7-fold higher than in HIV-negative populations, indicating that mechanisms beyond CD4+ T-cell depletion contribute to persistent TB susceptibility. Autophagy is a conserved lysosomal degradation pathway essential for intracellular pathogen clearance and immune regulation, and its dysregulation has emerged as a critical determinant of host-pathogen interactions in HIV/TB co-infection. In this review, we synthesize current evidence suggesting that HIV profoundly suppresses autophagy in key immune cells through the concerted actions of viral proteins, including Nef, Tat, and Env, through the off-target effects of ART drugs. This inhibition may disrupt macrophage antimicrobial functions, including phagosome maturation, xenophagy, and LC3-associated phagocytosis, while also impairing antigen presentation in dendritic cells. These defects may compromise communication between immune cells, attenuate T-cell responses, and create a permissive intracellular niche for Mycobacterium tuberculosis (Mtb) survival and proliferation. We propose an integrated mechanistic framework linking HIV-driven autophagy suppression to enhanced TB susceptibility, highlighting the synergistic interplay between HIV proteins and Mtb evasion strategies. By elucidating these molecular connections, we identify autophagy as a promising therapeutic target and highlight autophagy-directed host-directed therapies as a potential strategy to reduce the persistent TB burden in PLWH and advance toward a cure for both infections.